EyePoint Pharmaceuticals, Inc

(NASDAQ:EYPT)

Latest On EyePoint Pharmaceuticals, Inc (EYPT):

Date/Time Type Description Signal Details
2023-05-30 14:28 ESTNewsEyePoint Pharmaceuticals: A Puncher's Chance For Long Acting Eye Disease Drug SuccessN/A
2023-05-18 19:57 ESTNewsAlimera jumps 48% on deal with EyePoint for eye disorder therapy YutiqN/A
2023-05-04 11:48 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) Q1 2023 Earnings Call TranscriptN/A
2023-05-03 23:29 ESTNewsEyePoint stock soars 20% after Q1 sees growth in Yutiq salesN/A
2023-05-03 10:09 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$0.56 beats by $0.13, revenue of $7.68M beats by $0.11MN/A
2023-05-02 22:14 ESTNewsEyePoint Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-03-02 16:14 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$1.16 misses by $0.54, revenue of $10.53M beats by $0.13MN/A
2023-03-02 16:13 ESTNewsEyePoint stock dips as Q4 net loss widens, revenue fallsN/A
2023-03-02 16:13 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) Q4 2022 Earnings Call TranscriptN/A
2023-03-02 01:38 ESTNewsEyePoint Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-02-27 14:25 ESTNewsRallybio, EyePoint in collaboration for geographic atrophy therapyN/A
2023-01-23 14:54 ESTNewsEyePoint inks lease for setting up of new manufacturing facility in MassachusettsN/A
2023-01-04 19:07 ESTNewsEyePoint Pharmaceuticals promotes Jay S. Duker to PresidentN/A
2022-11-02 16:59 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$0.49 beats by $0.16, revenue of $10.01M misses by $0.91MN/A
2022-11-02 16:58 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) Q3 2022 Earnings Call TranscriptN/A
2022-08-30 20:33 ESTNewsEyePoint Pharma stock tumbles 14% postmarket on subpoena related to Dexycu salesN/A
2022-08-30 04:14 ESTNewsEyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD SpaceN/A
2022-08-03 20:25 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$0.52 misses by $0.01, revenue of $11.6M beats by $0.74MN/A
2022-08-03 20:24 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2022 Results - Earnings Call TranscriptN/A
2022-07-19 02:49 ESTNewsEyePoint reports preliminary Q2 net product revenue $11.3MN/A
2022-07-15 12:59 ESTNewsEyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMDN/A
2022-06-22 02:08 ESTNewsEyePoint, OcuMension's eye implant therapy implant Yutiq gets approval in ChinaN/A
2022-05-05 03:05 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$0.56 in-line, revenue of $9.3M misses by $0.59MN/A
2022-05-05 03:05 ESTNewsEyePoint Q1 net loss widens Y/Y; inks license deal with China's Betta for EYP-1901N/A
2022-05-05 03:04 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2022 Earnings Call TranscriptN/A
2022-05-03 13:09 ESTNewsEyePoint Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-03-09 23:17 ESTNewsEyePoint Pharmaceuticals signs loan agreement for $45M with Silicon Valley BankN/A
2022-03-04 04:42 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-03 11:12 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$0.59 misses by $0.03, revenue of $11.54M beats by $1.75MN/A
2022-03-02 16:55 ESTNewsEyePoint Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-02-14 07:42 ESTNewsEyePoint Pharmaceuticals reports positive data EYP-1901 data for the treatment of wet AMDN/A
2021-12-08 06:00 ESTNewsEyePoint, ImprimisRx expand commercial alliance for Dexycu eye corticosteroidN/A
2021-11-20 08:20 ESTNewsEyepoint Pharmaceuticals (EYPT) Investor Presentation - SlideshowN/A
2021-11-17 17:02 ESTNewsEyePoint Pharma secures $100M capital raise via equity offeringN/A
2021-11-17 17:01 ESTNewsShares of EyePoint Pharma soar 27% after pricing $100M equity offeringN/A
2021-11-16 20:09 ESTNewsEyePoint Pharma slumps on offering of $100M common sharesN/A
2021-11-15 05:04 ESTNewsEyePoint Pharma reports positive EYP-1901 data for treatment of wet AMDN/A
2021-11-04 08:34 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-03 11:51 ESTNewsEyePoint Pharmaceuticals EPS misses by $0.18, misses on revenueN/A
2021-11-02 15:45 ESTNewsEyePoint Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-10-13 00:22 ESTNewsEyePoint says its wet AMD therapy posed no serious adverse events in early studyN/A
2021-08-05 04:20 ESTNewsEyePoint Pharmaceuticals EPS beats by $0.09, beats on revenueN/A
2021-08-05 04:17 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-21 07:32 ESTNewsEyePoint Pharmaceuticals to join Russell 2000 and 3000 IndexN/A
2021-07-21 07:24 ESTNewsEyePoint Pharma reports positive EYP-1901 results in wet-AMDN/A
2021-05-05 15:43 ESTNewsEyePoint Pharmaceuticals EPS beats by $0.01, misses on revenueN/A
2021-05-05 15:39 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2021 Results - Earnings Call TranscriptN/A
2021-04-23 12:43 ESTNewsEyePoint Pharmaceuticals End Of Year Earnings Call AnalysisN/A
2021-03-06 07:38 ESTFinancialsCompany financials have been released.Neutral
2021-03-05 07:43 ESTEarnings EstimateAn EPS average of -$0.89 is estimated for the 2022 year.Buy

About EyePoint Pharmaceuticals, Inc (EYPT):

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.

EYPT Quotes by TradingView

See Advanced Chart

General

  • Name EyePoint Pharmaceuticals, Inc
  • Symbol EYPT
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Last Split Factor1:10
  • Last Split Date2020-12-09
  • Fiscal Year EndDecember
  • IPO Date2005-01-27
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://eyepointpharma.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 3.93
  • Price/Book (Most Recent Quarter) 16.32
  • Enterprise Value Revenue 8.65
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.71
  • Next Year EPS Estimate -$1.43
  • Next Quarter EPS Estimate -$0.62
  • Profit Margin -132%
  • Operating Margin -107%
  • Return on Assets -28%
  • Return on Equity -338%
  • Revenue 34.44 million
  • Earnings Per Share -$0.72
  • Revenue Per Share $2.68
  • Gross Profit 11.19 million
  • Quarterly Earnings Growth -17.4%
View More

Highlights

  • Market Capitalization 317.88 million
  • EBITDA -56213000
  • Analyst Target Price $19.25
  • Book Value Per Share $1.02
View More

Share Statistics

  • Shares Outstanding 28.74 million
  • Shares Float 19.88 million
  • % Held by Insiders 73%
  • % Held by Institutions 46.62%
  • Shares Short 381742
  • Shares Short Prior Month 350229
  • Short Ratio 0.8
  • Short % of Float 2%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 1.33
  • 52 Week High $15.06
  • 52 Week Low $3.51
  • 50 Day Moving Average 12.02
  • 200 Day Moving Average 7.3
View More

Dividends

  • Dividend Date 2020-12-09
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

EyePoint Pharmaceuticals, Inc (EYPT) Dividend Calendar:

EYPT's last dividend payment was made to shareholders on December 9, 2020.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

EyePoint Pharmaceuticals, Inc (EYPT) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-04$7.13 million-$1.07-$0.17-536.9%
2020-09-302020-11-05$N/A-$0.30-$0.3718.19%
2020-06-302020-08-05$N/A-$1.00-$1.109.09%
2020-03-312020-05-06$7.49 million-$1.10-$0.97-13.79%
2019-12-312020-03-05$8.63 million-$1.00-$1.1513.04%
2019-09-302019-11-07$2.51 million-$1.50-$1.25-20%
2019-06-302019-08-07$7.21 million-$1.10-$1.4021.43%
2019-03-312019-05-08$2.01 million-$2.00-$0.90-122.22%
2018-12-312019-03-14$2.44 million-$1.20-$1.4014.29%
2018-09-302018-11-06$486000-$0.44-$0.15-193.33%
2018-06-302018-09-12$715000-$6.20-$1.07-481.23%
2018-03-312018-05-08$928000-$1.50-$1.30-15.38%
2017-12-312018-02-07$933000-$1.30-$1.5013.33%
2017-09-302017-11-07$385000-$1.50-$1.500%
2017-06-302017-09-11$701000-$1.60-$1.50-6.67%
2017-03-312017-05-04$590000-$1.50-$1.500%
2016-12-312017-02-07$5.97 million$-0.00-$1.8399.89%
2016-09-302016-11-07$277000-$2.10-$1.90-10.53%
2016-06-302016-09-12$304000-$1.90-$1.25-52%
2016-03-312016-05-05$324000-$1.50-$1.9523.08%
2015-12-312016-02-08$526000-$1.80-$1.50-20%
2015-09-302015-11-05$466000-$0.17-$0.14-21.43%
2015-06-302015-09-09$409000-$0.17-$0.13-30.77%
2015-03-312015-05-08$328000-$0.17-$0.13-30.77%
2014-12-312015-02-05$521000-$0.14-$0.13-7.69%
2014-09-302014-11-07$25.31 million$0.67-$0.12658.33%
2014-06-302014-09-09$292000-$0.14-$0.140%
2014-03-312014-05-13$1.99 million-$0.08-$0.1546.67%
2013-12-312014-02-07$592000-$0.13-$0.130%
2013-09-302013-11-12$597000-$0.14-$0.13-7.69%
2013-06-302013-09-25$492000-$0.17-$0.12-41.67%
2013-03-312013-05-13$513000-$0.12-$0.137.69%
2012-12-312013-02-06$585000-$0.11-$0.1315.38%
2012-09-302012-11-08$553000-$0.11-$0.10-10%
2012-06-302012-09-24$699000-$0.11-$0.1942.11%
2012-03-312012-05-09$538000-$0.13-$0.1723.53%
2011-12-312012-02-08$630000-$0.13-$0.1723.53%
2011-09-302011-11-07$1.66 million-$0.12-$0.2142.86%
2011-06-302011-09-12$3.72 million-$0.01-$0.1894.44%
2011-03-312011-05-10$360000-$0.13-$0.2138.1%
2010-12-312011-02-09$414000-$0.15$0.45-133.33%
2010-09-302010-11-05$476000-$0.17-$0.14-21.43%
2010-06-302010-09-23$15.72 million$6.80
2010-03-312010-05-12$515000-$0.15-$0.1922.95%
2009-12-312010-02-12$3.43 million-$0.01
2009-09-302009-11-13$3.38 million-$0.87
2009-06-302009-09-25$3.22 million-$0.29
2009-03-312009-05-13$3.16 million-$0.35
2008-12-312009-02-11$2.97 million-$0.48
2008-09-302008-11-11$2.81 million-$0.26
2008-06-302008-06-30$2.7 million-$35.00
2008-03-312008-03-31$542000-$12.05
2007-12-312007-12-31$128000-$12.70
2007-09-302007-09-30$103000-$1.78

EyePoint Pharmaceuticals, Inc (EYPT) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

EyePoint Pharmaceuticals, Inc (EYPT) Chart:

EyePoint Pharmaceuticals, Inc (EYPT) News:

Below you will find a list of latest news for EyePoint Pharmaceuticals, Inc (EYPT) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

EyePoint Pharmaceuticals, Inc (EYPT) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-07-172.512.35CALL0 20TRUE00
2026-07-1759.7CALL0 89399.48TRUE00
2026-07-177.57.3CALL0 1560TRUE00
2026-07-17104.85CALL0 188155.67TRUE00
2026-07-1712.52.36CALL0 11796.63TRUE00
2026-07-17150.45CALL0 621122.43FALSE00
2026-07-1717.50.07CALL0 59388.11FALSE00
2026-07-17200.08CALL0 535137.19FALSE00
2026-07-1722.50CALL0 78372.02FALSE00
2026-07-17250CALL0 205420.96FALSE00
2026-07-17300CALL0 1823441.02FALSE00
2026-07-17350CALL0 10561.8FALSE00
2026-07-172.50PUT0 0638.52FALSE00
2026-07-1750PUT0 1761.58FALSE00
2026-07-177.50PUT0 0619.29FALSE00
2026-07-17100PUT0 43331.38FALSE00
2026-07-1712.50PUT0 73097.46FALSE00
2026-07-17150PUT0 60112.89TRUE00
2026-07-1717.50PUT0 18221.27TRUE00
2026-07-17205.65PUT6 137237.81TRUE5.650
2026-07-1722.58.2PUT4 3192.73TRUE8.20
2026-07-17250PUT0 1251.89TRUE00
2026-07-17300PUT0 00TRUE00
2026-07-17350PUT0 00TRUE00
2026-08-212.512.25CALL0 10TRUE00
2026-08-2150CALL0 1280TRUE00
2026-08-217.57.72CALL5 80179.66TRUE7.720
2026-08-21106.94CALL0 149239.83TRUE00
2026-08-2112.50CALL0 35232.85TRUE00
2026-08-21153.9CALL0 44235.9FALSE00
2026-08-2117.53.3CALL8 810249.21FALSE-0.3-0.08
2026-08-21200CALL0 19241.67FALSE00
2026-08-2122.50CALL0 124230.95FALSE00
2026-08-21250CALL0 89242.58FALSE00
2026-08-21300CALL0 2219.59FALSE00
2026-08-21351CALL1 4223.19FALSE10
2026-08-212.50PUT0 0390.61FALSE00
2026-08-2150PUT0 2314.08FALSE00
2026-08-217.51.2PUT2 39262.1FALSE1.20
2026-08-21102.2PUT325 3358257.46FALSE0.050.02
2026-08-2112.53.7PUT2 1893277.17FALSE0.20.06
2026-08-21150PUT0 12259.35TRUE00
2026-08-2117.50PUT0 0220.01TRUE00
2026-08-21200PUT0 228259.07TRUE00
2026-08-2122.50PUT0 16233.45TRUE00
2026-08-21250PUT0 0228.33TRUE00
2026-08-21300PUT0 0222.01TRUE00
2026-08-21350PUT0 0234.94TRUE00
2026-09-182.50CALL0 0172.21TRUE00
2026-09-1850CALL0 0198.72TRUE00
2026-09-187.50CALL0 2279.54TRUE00
2026-09-18100CALL0 5265.91TRUE00
2026-09-1812.50CALL0 0266.6TRUE00
2026-09-18156.8CALL26 25278.42FALSE6.80
2026-09-1817.50CALL0 115242.75FALSE00
2026-09-18200CALL0 27241.27FALSE00
2026-09-1822.50CALL0 4246.38FALSE00
2026-09-18250CALL0 161252.62FALSE00
2026-09-18303.2CALL12 1260.03FALSE3.20
2026-09-182.50PUT0 0277.9FALSE00
2026-09-1851.1PUT2 0301.07FALSE1.10
2026-09-187.51.9PUT4 4257.84FALSE1.90
2026-09-18100PUT0 1250.18FALSE00
2026-09-1812.54.35PUT3 192274.23FALSE4.350
2026-09-18150PUT0 0272.04TRUE00
2026-09-1817.50PUT0 0254.43TRUE00
2026-09-18200PUT0 0250.96TRUE00
2026-09-1822.50PUT0 0250.41TRUE00
2026-09-18250PUT0 0253.16TRUE00
2026-09-18300PUT0 0240.73TRUE00
2026-10-162.50CALL0 0180.96TRUE00
2026-10-16510.05CALL0 1235.12TRUE00
2026-10-167.58.85CALL0 3248.26TRUE00
2026-10-16100CALL0 23257.11TRUE00
2026-10-1612.50CALL0 24250.7TRUE00
2026-10-16150CALL0 24252.41FALSE00
2026-10-1617.50CALL0 3970233.18FALSE00
2026-10-16205.78CALL0 163261.12FALSE00
2026-10-1622.50CALL0 60232.73FALSE00
2026-10-16254CALL0 3705232.69FALSE00
2026-10-16300CALL0 51226.43FALSE00
2026-10-16354CALL909 475219.6FALSE1.050.36
2026-10-162.50PUT0 2375.09FALSE00
2026-10-1650PUT0 10274.2FALSE00
2026-10-167.52.6PUT76 5183272.31FALSE0.050.02
2026-10-16100PUT0 25026254.94FALSE00
2026-10-1612.50PUT0 112281.83FALSE00
2026-10-16150PUT0 3803260.48TRUE00
2026-10-1617.50PUT0 191262TRUE00
2026-10-16200PUT0 0251.46TRUE00
2026-10-1622.50PUT0 4243.06TRUE00
2026-10-16250PUT0 2233.28TRUE00
2026-10-16300PUT0 2224.71TRUE00
2026-10-16350PUT0 0221.29TRUE00
2026-12-182.50CALL0 3192.12TRUE00
2026-12-1850CALL0 94205.18TRUE00
2026-12-187.50CALL0 151202.53TRUE00
2026-12-18100CALL0 171201.32TRUE00
2026-12-1812.50CALL0 68203.18TRUE00
2026-12-18158.2CALL26 2155232.08FALSE8.20
2026-12-1817.50CALL0 605195.38FALSE00
2026-12-18200CALL0 55192.76FALSE00
2026-12-1822.55.5CALL1 98191.27FALSE5.50
2026-12-18250CALL0 75185.79FALSE00
2026-12-18300CALL0 151188.6FALSE00
2026-12-18350CALL0 1099169.79FALSE00
2026-12-182.50PUT0 0312.46FALSE00
2026-12-1850PUT0 149233.7FALSE00
2026-12-187.50PUT0 5219.84FALSE00
2026-12-18100PUT0 104224.99FALSE00
2026-12-1812.50PUT0 403221.17FALSE00
2026-12-18150PUT0 1216.07TRUE00
2026-12-1817.50PUT0 2212.11TRUE00
2026-12-18200PUT0 0200.82TRUE00
2026-12-1822.50PUT0 0198.42TRUE00
2026-12-18250PUT0 1196.07TRUE00
2026-12-18300PUT0 0190.88TRUE00
2026-12-18350PUT0 0188.78TRUE00
2027-01-152.50CALL0 67175.98TRUE00
2027-01-15511.4CALL0 4188.63TRUE00
2027-01-157.50CALL0 2186.31TRUE00
2027-01-15100CALL0 1187.18TRUE00
2027-01-1512.50CALL0 7187.04TRUE00
2027-01-15150CALL0 9201.22FALSE00
2027-01-1517.55.8CALL1 16173.13FALSE5.80
2027-01-15206CALL0 16180.09FALSE00
2027-01-1522.50CALL0 0178.63FALSE00
2027-01-15250CALL0 7173.52FALSE00
2027-01-15300CALL0 1178.47FALSE00
2027-01-15350CALL0 18176.69FALSE00
2027-01-152.50PUT0 0296.07FALSE00
2027-01-1550PUT0 1205.49FALSE00
2027-01-157.50PUT0 2198.56FALSE00
2027-01-15100PUT0 2191.74FALSE00
2027-01-1512.50PUT0 10193.08FALSE00
2027-01-15157.6PUT0 3198.72TRUE00
2027-01-1517.50PUT0 0189.68TRUE00
2027-01-15200PUT0 0187.66TRUE00
2027-01-1522.50PUT0 0184.22TRUE00
2027-01-15250PUT0 0184.6TRUE00
2027-01-15300PUT0 0179.93TRUE00
2027-01-15350PUT0 0180.58TRUE00
2028-01-212.50CALL0 0143.24TRUE00
2028-01-2150CALL0 1137.18TRUE00
2028-01-217.50CALL0 0126.34TRUE00
2028-01-21100CALL0 48146.83TRUE00
2028-01-2112.50CALL0 0125.81TRUE00
2028-01-21150CALL0 13127.21FALSE00
2028-01-2117.50CALL0 0127.06FALSE00
2028-01-21200CALL0 2125.93FALSE00
2028-01-2122.50CALL0 0120.22FALSE00
2028-01-21250CALL0 27121.88FALSE00
2028-01-21300CALL0 3116.29FALSE00
2028-01-212.50PUT0 00FALSE00
2028-01-2150PUT0 0170.32FALSE00
2028-01-217.53.1PUT30 20141FALSE3.10
2028-01-21100PUT0 10139.27FALSE00
2028-01-2112.50PUT0 0132.71FALSE00
2028-01-21150PUT0 0125.87TRUE00
2028-01-2117.50PUT0 0127.51TRUE00
2028-01-21200PUT0 2127.89TRUE00
2028-01-2122.50PUT0 0127.41TRUE00
2028-01-21250PUT0 0126.3TRUE00
2028-01-21300PUT0 0122.65TRUE00

Latest EYPT Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST10$7.555
Jun 13, 2022 7:59 PM EST4$7.555
Jun 13, 2022 7:59 PM EST32$7.555
Jun 13, 2022 7:59 PM EST5$7.53
Jun 13, 2022 7:59 PM EST100$7.53

EyePoint Pharmaceuticals, Inc (EYPT) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004870/0001562180-20-004870-index.htm
2018-11-30UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1314102/000000000018036896/0000000000-18-036896-index.htm
2018-11-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000089924318029124/0000899243-18-029124-index.htm
2018-12-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000089924318031698/0000899243-18-031698-index.htm
2019-02-135Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000089924319003415/0000899243-19-003415-index.htm
2018-10-31S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1314102/000119312518314121/0001193125-18-314121-index.htm
2018-11-01CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1314102/000119312518315426/0001193125-18-315426-index.htm
2018-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312518318982/0001193125-18-318982-index.htm
2018-11-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000119312518323795/0001193125-18-323795-index.htm
2018-11-28S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1314102/000119312518336713/0001193125-18-336713-index.htm
2018-12-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1314102/000119312518345921/0001193125-18-345921-index.htm
2019-01-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519002516/0001193125-19-002516-index.htm
2019-01-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519008307/0001193125-19-008307-index.htm
2019-01-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519012973/0001193125-19-012973-index.htm
2019-01-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312519012979/0001193125-19-012979-index.htm
2019-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519020750/0001193125-19-020750-index.htm
2019-02-13SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1314102/000119312519037699/0001193125-19-037699-index.htm
2019-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519044197/0001193125-19-044197-index.htm
2019-03-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519073987/0001193125-19-073987-index.htm
2019-03-1810-KTTransition reports [Rule 13a-10 or 15d-10]https://www.sec.gov/Archives/edgar/data/1314102/000119312519078454/0001193125-19-078454-index.htm
2019-03-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312519088540/0001193125-19-088540-index.htm
2019-03-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312519092951/0001193125-19-092951-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519094684/0001193125-19-094684-index.htm
2019-04-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519121055/0001193125-19-121055-index.htm
2019-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314102/000119312519125776/0001193125-19-125776-index.htm
2019-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314102/000119312519125782/0001193125-19-125782-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519140432/0001193125-19-140432-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000119312519144237/0001193125-19-144237-index.htm
2019-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519153328/0001193125-19-153328-index.htm
2019-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519185970/0001193125-19-185970-index.htm
2019-07-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519192395/0001193125-19-192395-index.htm
2019-07-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519195624/0001193125-19-195624-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519214582/0001193125-19-214582-index.htm
2019-08-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1314102/000119312519216909/0001193125-19-216909-index.htm
2020-02-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312520043553/0001193125-20-043553-index.htm
2020-02-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312520046322/0001193125-20-046322-index.htm
2020-08-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312520210092/0001193125-20-210092-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312520217649/0001193125-20-217649-index.htm
2020-11-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1314102/000119312520287418/0001193125-20-287418-index.htm
2019-01-293Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019000562/0001562180-19-000562-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019000563/0001562180-19-000563-index.htm
2019-03-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002006/0001562180-19-002006-index.htm
2019-03-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002007/0001562180-19-002007-index.htm
2019-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002053/0001562180-19-002053-index.htm
2019-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002054/0001562180-19-002054-index.htm
2019-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002055/0001562180-19-002055-index.htm
2019-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002080/0001562180-19-002080-index.htm
2019-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002168/0001562180-19-002168-index.htm
2019-04-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002284/0001562180-19-002284-index.htm
2019-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002822/0001562180-19-002822-index.htm
2019-06-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003506/0001562180-19-003506-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003509/0001562180-19-003509-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003560/0001562180-19-003560-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003561/0001562180-19-003561-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003562/0001562180-19-003562-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003626/0001562180-19-003626-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003627/0001562180-19-003627-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003628/0001562180-19-003628-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003629/0001562180-19-003629-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003630/0001562180-19-003630-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003660/0001562180-19-003660-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003661/0001562180-19-003661-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003662/0001562180-19-003662-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003663/0001562180-19-003663-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003664/0001562180-19-003664-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003665/0001562180-19-003665-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003666/0001562180-19-003666-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003667/0001562180-19-003667-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003668/0001562180-19-003668-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003669/0001562180-19-003669-index.htm
2019-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003675/0001562180-19-003675-index.htm
2019-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003676/0001562180-19-003676-index.htm
2019-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003677/0001562180-19-003677-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003958/0001562180-19-003958-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003959/0001562180-19-003959-index.htm
2019-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019004701/0001562180-19-004701-index.htm
2019-10-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019005150/0001562180-19-005150-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019005159/0001562180-19-005159-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019005160/0001562180-19-005160-index.htm
2019-11-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019005547/0001562180-19-005547-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019005548/0001562180-19-005548-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020001682/0001562180-20-001682-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002036/0001562180-20-002036-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002042/0001562180-20-002042-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002043/0001562180-20-002043-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002044/0001562180-20-002044-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002045/0001562180-20-002045-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002046/0001562180-20-002046-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002047/0001562180-20-002047-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002048/0001562180-20-002048-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002049/0001562180-20-002049-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002050/0001562180-20-002050-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002051/0001562180-20-002051-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002054/0001562180-20-002054-index.htm
2020-03-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002379/0001562180-20-002379-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002451/0001562180-20-002451-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004516/0001562180-20-004516-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004517/0001562180-20-004517-index.htm
2020-06-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004716/0001562180-20-004716-index.htm
2020-06-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004723/0001562180-20-004723-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004867/0001562180-20-004867-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004869/0001562180-20-004869-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004870/0001562180-20-004870-index.htm
2020-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020005659/0001562180-20-005659-index.htm
2020-09-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020005930/0001562180-20-005930-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000156459019029987/0001564590-19-029987-index.htm
2019-08-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019032836/0001564590-19-032836-index.htm
2019-09-098-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019034357/0001564590-19-034357-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019041352/0001564590-19-041352-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000156459019041819/0001564590-19-041819-index.htm
2019-11-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019043812/0001564590-19-043812-index.htm
2019-11-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019044172/0001564590-19-044172-index.htm
2019-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019044762/0001564590-19-044762-index.htm
2020-01-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020000993/0001564590-20-000993-index.htm
2020-01-168-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020001223/0001564590-20-001223-index.htm
2020-01-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020001745/0001564590-20-001745-index.htm
2020-02-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020003097/0001564590-20-003097-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020005550/0001564590-20-005550-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020006023/0001564590-20-006023-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020008797/0001564590-20-008797-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314102/000156459020010956/0001564590-20-010956-index.htm
2020-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020015451/0001564590-20-015451-index.htm
2020-04-17PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1314102/000156459020017306/0001564590-20-017306-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314102/000156459020019026/0001564590-20-019026-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314102/000156459020019028/0001564590-20-019028-index.htm
2020-04-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020019253/0001564590-20-019253-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020021535/0001564590-20-021535-index.htm
2020-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000156459020023640/0001564590-20-023640-index.htm
2020-06-04DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314102/000156459020028332/0001564590-20-028332-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020029661/0001564590-20-029661-index.htm
2020-06-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020030273/0001564590-20-030273-index.htm
2020-07-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020032264/0001564590-20-032264-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020036425/0001564590-20-036425-index.htm
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000156459020036429/0001564590-20-036429-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020036461/0001564590-20-036461-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020037729/0001564590-20-037729-index.htm
2020-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020040715/0001564590-20-040715-index.htm
2020-09-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020043596/0001564590-20-043596-index.htm
2020-10-06PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1314102/000156459020045941/0001564590-20-045941-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020045966/0001564590-20-045966-index.htm
2020-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020046049/0001564590-20-046049-index.htm
2020-10-16DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314102/000156459020046585/0001564590-20-046585-index.htm
2020-10-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314102/000156459020046623/0001564590-20-046623-index.htm
2020-10-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314102/000156459020046655/0001564590-20-046655-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020050850/0001564590-20-050850-index.htm
2020-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000156459020051654/0001564590-20-051654-index.htm
2018-11-01EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314102/999999999518002780/9999999995-18-002780-index.htm
2018-12-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314102/999999999518003103/9999999995-18-003103-index.htm

EyePoint Pharmaceuticals, Inc (EYPT) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of EyePoint Pharmaceuticals, Inc (EYPT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 73%
Institutional Ownership: 4662%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-11-15George ElstonChief Financial OfficerBuy10,000.001.4314,290.0010,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019005548/0001562180-19-005548-index.htm
2020-06-30Dario A. PaggiarinoChief Medical OfficerBuy41,050.00101,193.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004869/0001562180-20-004869-index.htm
2018-11-15MICHAEL W ROGERSDirectorBuy100,000.001.13113,000.00112,500.00https://www.sec.gov/Archives/edgar/data/1314102/000089924318029124/0000899243-18-029124-index.htm
2019-06-21MICHAEL W ROGERSDirectorBuy6,667.00119,167.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003630/0001562180-19-003630-index.htm
2019-03-29David J MazzoDirectorBuy20,000.001.7735,400.00158,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002054/0001562180-19-002054-index.htm
2019-06-21David J MazzoDirectorBuy8,333.00166,333.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003629/0001562180-19-003629-index.htm
2019-09-06David J MazzoDirectorBuy417.00166,750.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019004701/0001562180-19-004701-index.htm
2019-04-01Jay S. DukerDirectorBuy5,000.001.899,450.0017,500.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002168/0001562180-19-002168-index.htm
2020-03-12George ElstonChief Financial OfficerBuy10,000.000.969,600.0020,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020002451/0001562180-20-002451-index.htm
2019-10-09David J MazzoDirectorBuy33,333.001.9564,999.35200,083.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019005150/0001562180-19-005150-index.htm
2019-03-29Nancy LurkerPresident & CEOBuy28,500.001.7650,245.50240,200.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002055/0001562180-19-002055-index.htm
2019-06-14Nancy LurkerPresident & CEOBuy45,000.00285,200.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003562/0001562180-19-003562-index.htm
2019-03-29Douglas Evan GodshallDirectorBuy17,000.001.7529,784.0029,500.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002053/0001562180-19-002053-index.htm
2020-08-24George ElstonChief Financial OfficerBuy10,000.000.616,112.0030,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020005659/0001562180-20-005659-index.htm
2019-06-27Nancy LurkerPresident & CEOBuy40,000.00325,200.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003675/0001562180-19-003675-index.htm
2019-06-21Douglas Evan GodshallDirectorBuy6,667.0036,167.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003627/0001562180-19-003627-index.htm
2019-04-12Jay S. DukerDirectorBuy20,000.001.7735,400.0037,500.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002284/0001562180-19-002284-index.htm
2020-09-04George ElstonChief Financial OfficerBuy10,000.000.484,800.0040,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020005930/0001562180-20-005930-index.htm
2019-05-13John B. LandisDirectorBuy40,000.001.7469,600.0040,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002822/0001562180-19-002822-index.htm
2020-06-30David Scott JonesSVP & Chief Commercial OfficerBuy41,050.0041,050.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004870/0001562180-20-004870-index.htm
2019-06-14Dario A. PaggiarinoChief Medical OfficerBuy14,200.0042,612.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003560/0001562180-19-003560-index.htm
2019-06-21Jay S. DukerDirectorBuy6,667.0044,167.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003626/0001562180-19-003626-index.htm
2020-02-21Nancy LurkerPresident & CEOBuy137,174.00476,800.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020001682/0001562180-20-001682-index.htm
2019-06-27Dario A. PaggiarinoChief Medical OfficerBuy10,000.0048,437.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003676/0001562180-19-003676-index.htm
2020-06-14Dario A. PaggiarinoChief Medical OfficerBuy14,200.0057,247.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004516/0001562180-20-004516-index.htm
2020-03-10Nancy LurkerPresident & CEOBuy98,000.001.06104,027.00574,800.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020002379/0001562180-20-002379-index.htm
2020-06-14Nancy LurkerPresident & CEOBuy45,000.00619,800.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004517/0001562180-20-004517-index.htm
2020-06-27Dario A. PaggiarinoChief Medical OfficerBuy10,000.0063,079.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004723/0001562180-20-004723-index.htm
2020-06-27Nancy LurkerPresident & CEOBuy40,000.00659,800.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004716/0001562180-20-004716-index.htm
2019-06-21Kristine PetersonDirectorBuy6,667.006,667.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003628/0001562180-19-003628-index.htm
2020-06-30Nancy LurkerPresident & CEOBuy124,667.00784,467.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004867/0001562180-20-004867-index.htm
2019-04-01Leonard S RossOfficerBuy5,000.001.819,050.0079,452.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002080/0001562180-19-002080-index.htm
2019-06-14Leonard S RossOfficerBuy8,280.0087,732.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003561/0001562180-19-003561-index.htm
2019-06-27Leonard S RossOfficerBuy6,667.0092,005.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003677/0001562180-19-003677-index.htm
2018-12-22Leonard S RossOfficerBuy62,892.0094,709.00https://www.sec.gov/Archives/edgar/data/1314102/000089924318031698/0000899243-18-031698-index.htm